Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants

Launched by SANOFI · Sep 7, 2018

Keywords

ClinConnect Summary

The total study duration per subject is expected to last up to 4.5 months, depending on the timing of the screening visit.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Males or females between the ages of 18 and 65 suffering from seasonal allergic rhinitis provoked by ragweed pollen.
• • Having a 2-year history of seasonal allergic rhinitis with positive skin prick test to ragweed allergen at screening with a wheal diameter at least 3 mm larger than that produced by the negative control.
• • Subjects with antecedents of allergic seasonal allergic rhinitis symptom aggravation when exposed to pollen and air pollutants (i.e., cleaning products, diesel, paints).
• • Subjects having a total nasal symptom score ≥3 in Period 1 (Visit 2).
• Exclusion criteria:
• • History of anaphylaxis to ragweed pollen.
• • History of asthma. Mild asthmatics treated only with pro re nata short-acting beta2-agonists, 2 doses or less per week can be enrolled.
• • History of chronic sinusitis.
• • History of systemic disease affecting the immune system.
• • Evidence of any active or suspected bacterial, viral, fungal or parasitic infections within 30 days prior to allergen challenge.
• • Any history of Grade 4 anaphylaxis due to any cause as defined by the Common Terminology Criteria for Adverse Event grading criteria ("Life threatening consequences: urgent intervention indicated").
• • Presence or history of drug hypersensitivity to fexofenadine.
• • Subjects receiving build-up injections of pollen allergen immunotherapy (those on stable maintenance dosing can be included).
• • Subjects taking any forbidden treatments/nutriments.
• • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.